Showing results (121-130 of 143) with videos related to

Sort By:
Pageof 15
BMC Cancer|August 15, 2024
Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNAJennifer H Chen, Sridevi Addanki, Dhruvajyoti Roy, et al.
Transplantation and Cellular Therapy|May 9, 2021
Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled TrialSairah Ahmed, Qaiser Bashir, Roland Bassett, et al.
Bone Marrow Transplantation|May 24, 2022
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantationBorje S Andersson, Peter F Thall, Junsheng Ma, et al.
Leukemia & Lymphoma|October 13, 2011
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplantStefan O Ciurea, Rima M Saliba, Nelson Hamerschlak, et al.
Cancers|November 13, 2025
Mutational Landscape and Clinical Impact of SPEN Mutations in Patients with Chronic Lymphocytic LeukemiaPriyatharsini Nirmalanantham, Andrés E Quesada, Anindita Ghosh, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 17, 2012
Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantationStefan O Ciurea, Victor Mulanovich, Rima M Saliba, et al.
Cancers|March 10, 2022
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast CancerNour Abuhadra, Ryan Sun, Jennifer K Litton, et al.
Transplantation and Cellular Therapy|July 30, 2021
Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical TrialRohtesh S Mehta, Roland Bassett, Julianne Chen, et al.
Blood Advances|August 23, 2023
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbiditiesUday R Popat, Oren Pasvolsky, Roland Bassett, et al.
Bone Marrow Transplantation|May 6, 2022
KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myelomaMahmoud R Gaballa, Junsheng Ma, Mikael Rauf, et al.
Pageof 15